Matthew S. Holt serves as Executive at Bellerophon Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Matthew S. Holt has executed 10 insider transactions totaling $12.8M, demonstrating a bullish approach to their equity position. Their most recent transaction on Mar 29, 2023 involved selling 14,672 shares valued at $0.
Matthew S. Holt currently holds 14,672 shares of Bellerophon Therapeutics, Inc. (BLPH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew S. Holt has been a net buyer of BLPH stock. They have purchased $12.8M and sold $0 worth of shares.
Matthew S. Holt's most recent insider trade was on Mar 29, 2023, when they sold 14,672 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| May 12, 2022 | AVTR | $0 | Award | 6,693 | $N/A | Discretionary |
| Apr 1, 2022 | AVTR | $0 | Award | 1,215 | $N/A | Discretionary |
| Feb 16, 2022 | SGFY | $0 | Other | 7,916 | $N/A | Discretionary |
| Feb 16, 2021 | SGFY | $0 | Award | 7,916 | $N/A | Discretionary |
| Apr 28, 2016 | BLPH | $0 | Award | 18,232 | $N/A | Discretionary |
| Feb 19, 2015 | BLPH | $12.8M | Purchase | 1,070,166 | $12.00 | Discretionary |
| Feb 12, 2015 | BLPH | $0 | Disposition | 460,144 | $N/A | Discretionary |
| Feb 12, 2015 | BLPH | $0 | Award | 460,144 | $N/A | Discretionary |